We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Electroporation Device Helps Kill Cancer Cells

By HospiMedica International staff writers
Posted on 06 Nov 2012
A novel device causes pores in the membrane of cancer cells to open, thus significantly increasing the uptake of anticancer agents. More...


The OncoSec electroporation device is intended for use during chemotherapy and immunotherapy to open pores within the membranes of target cancer cells, making them more susceptible to injected compounds, thus improving therapy effectiveness and reducing systemic toxicity. The electroporation platform consists of a generator that creates a pulsed electric field that temporarily increases the porosity of cell membranes within the treatment field. A hand-held applicator then supplies a series of short-duration electrical pulses of specific voltage through a series of needles.

Together, the action of the generator and applicator creates a rotating array of pulses that uniformly subject the targeted cell membranes to electroporation. The electric fields generated are inert, and dissipate once the device is stopped, reducing concerns about residual long-term effects. Results from the phase I study have demonstrated that only one week of treatment could result in clinical benefit for late-stage cancer patients. The OncoSec electroporation device is a product of OncoSec Medical System (OMS; San Diego, CA, USA), and has received the European Community CE marking of approval.

“We strongly believe in the clinical relevance of our therapeutic approach,” said Said Punit Dhillon, president and CEO of OncoSec. “Clinical experience […] supports the uniqueness of OMS ElectroChemotherapy in its ability to achieve selective destruction of cancerous tumors while sparing healthy normal tissue including highly vascularized and innervated surrounding structures, providing physicians with an important flexible treatment alternative.”

The electroporation device currently works with two anticancer therapies: ImmunoPulse, which delivers instructions to the cell to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12 (DNA IL-12), which induces a cytokine cascade with antiangiogenic effects; and NeoPulse, which delivers bleomycin, an approved anticancer drug that specifically targets and destroys cancer cells.

Related Links:

OncoSec Medical System




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.